| Patents for A61P 21 - Drugs for disorders of the muscular or neuromuscular system (23,287) |
|---|
| 02/14/2002 | US20020019430 Nervous system and psychological disorders |
| 02/14/2002 | US20020019426 Therapy for amyotropic lateral sclerosis |
| 02/14/2002 | US20020019424 1-sulfonyl pyrrolidine derivatives |
| 02/14/2002 | US20020019393 Treating inflammation, autoimmune diseases, destructive bone disorders, proliferative disorders, infections, neurvous system disorders, reperfusion/ischemia in stroke, cardiovascular disorders, hypoxia, edema, fever, pain |
| 02/14/2002 | US20020019016 Classifying nervous system disorders; obtain tissue, detect preferential tau protein in sample |
| 02/14/2002 | US20020018809 Analgesics; rheumatic diseases; muscular disorders; sleep disorders |
| 02/14/2002 | US20020018787 Synergistic mixture of dimethylglycine and mussel extract |
| 02/14/2002 | CA2504880A1 Polymorphs of zaleplon and methods for the preparation thereof |
| 02/14/2002 | CA2423519A1 A new slit-like protein obtained from a cdna library from hs-5 stromal cell line |
| 02/14/2002 | CA2418912A1 Neuroprotective 2-pyridinamine compositions and related methods |
| 02/14/2002 | CA2418832A1 Quinolene derivatives as anti-inflammation agents |
| 02/14/2002 | CA2418445A1 Stress proteins and peptides and methods of use thereof |
| 02/14/2002 | CA2417587A1 Transporters and ion channels |
| 02/14/2002 | CA2412368A1 Benzimidazole derivatives, preparation and therapeutic use thereof |
| 02/13/2002 | EP1179065A2 Full-length molecules expressed in human tissues |
| 02/13/2002 | EP1179064A2 Secreted polypeptides and corresponding polynucleotides |
| 02/13/2002 | EP1179005A1 Steroid compounds with a c17-alkyl side chain and an aromatic a-ring for use in therapy |
| 02/13/2002 | EP1178981A1 Substituted 3-pyridyl-4-arylpyrroles, and related therapeutic and prophylactic methods |
| 02/13/2002 | EP1178977A1 Ion channel modulating agents |
| 02/13/2002 | EP1178958A2 N-cyanomethyl amides as protease inhibitors |
| 02/13/2002 | EP1178836A2 Use of chimeric mutational vectors to change endogenous sequences in solid tissues |
| 02/13/2002 | EP1178802A1 Cyclic amidines useful as nmda nr2b antagonists |
| 02/13/2002 | EP1178792A1 Aryl amidines, compositions containing such compounds and methods of use |
| 02/13/2002 | EP1178787A1 Pharmaceutical compositions for oral administration of phloroglucinol and preparation thereof |
| 02/13/2002 | EP0769957B1 Methods for treating motor deficits |
| 02/13/2002 | CN1335849A Pyrrolopyrimidines as protein kinase inhibitors |
| 02/12/2002 | US6346548 Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue |
| 02/12/2002 | US6346247 Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies |
| 02/12/2002 | CA2057504C Process for preparing new n-acyl-2,3-benzodiazepine derivatives, their acid addition salts and pharmaceutical compositions containing the same |
| 02/07/2002 | WO2002010387A2 G-protein coupled receptors |
| 02/07/2002 | WO2002010363A2 Protein phosphatases |
| 02/07/2002 | WO2002010214A2 Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
| 02/07/2002 | WO2002010141A1 Imidazole derivatives |
| 02/07/2002 | WO2002010139A1 Hexahydro-7-1h-azepin-2-yl-haxanoic acid derivatives as inhibitors of inducible nitric oxide synthase |
| 02/07/2002 | WO2002009756A1 Nerve regeneration promoters containing semaphorin inhibitor as the active ingredient |
| 02/07/2002 | WO2002009740A1 Composition containing an iron complexing protein and a precursor of nitrogen monoxide metabolism and/or a chemical donor of nitrogen monoxide and uses thereof |
| 02/07/2002 | WO2002009716A2 Use of an aldehyde 5-oxo-1,2,4-triazine hydrazide for the treatment of cancer |
| 02/07/2002 | WO2002009686A2 Cdc25 phosphatase inhibitors |
| 02/07/2002 | WO2001081310A8 1-aroyl-piperidinyl benzamidines |
| 02/07/2002 | WO2001062744A3 Substituted piperazine compounds |
| 02/07/2002 | US20020016625 Drug/drug delivery systems for the prevention and treatment of vascular disease |
| 02/07/2002 | US20020016465 Process for the preparation of the mesylate salt trihydrate of 1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanol |
| 02/07/2002 | US20020016354 Treatment of respiratory diseases, convulsions, vascular disorders, renal disorders, urinary disorders, Alzheimer's disease, dysmenorrhea, narcolepsy |
| 02/07/2002 | US20020016342 Combination therapy using COX-2 selective inhibitor and thromboxane inhibitor and compositions therefor |
| 02/07/2002 | US20020016336 Treatment of rheumatoid and osteoarthritis, corneal, epidermal or gastric ulceration, tumor metastasis or invasion, periodontal disease and bone disease |
| 02/07/2002 | US20020015981 Beta-like glycoprotein hormone polypeptide and heterodimer |
| 02/07/2002 | US20020015703 Monoclonal antibodies or soluble immunoglobulin fusion proteins to block the development of chronic Graft-Versus-Host Disease |
| 02/07/2002 | CA2418115A1 Imidazole derivatives |
| 02/07/2002 | CA2417568A1 Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
| 02/07/2002 | CA2417359A1 Protein phosphatases |
| 02/07/2002 | CA2417262A1 Cdc25 phosphatase inhibitors |
| 02/07/2002 | CA2417195A1 G-protein coupled receptors |
| 02/07/2002 | CA2416978A1 Use of an aldehyde 5-oxo-1,2,4-triazine hydrazide for the treatment of cancer |
| 02/07/2002 | CA2415851A1 Hexahydro-7-1h-azepin-2-yl-haxanoic acid derivatives as inhibitors of inducible nitric oxide synthase |
| 02/06/2002 | EP1177312A2 Human gil-19/ae289 proteins and polynucleotides encoding same |
| 02/06/2002 | EP1177297A2 Novel nucleic acids and proteins with growth hormone activity |
| 02/06/2002 | EP1177296A2 Extracellular matrix and adhesion-associated proteins |
| 02/06/2002 | EP1177287A2 Secreted human proteins |
| 02/06/2002 | EP1176985A2 Enzymatically activated polymeric drug conjugates |
| 02/06/2002 | EP1176981A1 Treatment of autoimmune diseases with antagonists which bind to b cell surface markers |
| 02/06/2002 | EP1176870A2 Tgf-alpha polypeptides, functional fragments and methods of use therefor |
| 02/06/2002 | EP0771198B1 Dihydro-2,3-benzodiazepine derivatives |
| 02/06/2002 | CN1334875A Cell signalling polypeptides and nucleic acids |
| 02/06/2002 | CN1334821A Humanized antibodies to gamma-interferon |
| 02/06/2002 | CN1334736A Modulation of immune response by ribavirin |
| 02/06/2002 | CN1334726A Hydroxy diphenyl urea sulfonamides as IL-8 receptor antagonists |
| 02/06/2002 | CN1334120A 'Futai'an' oral liquid |
| 02/05/2002 | US6344484 Treatment of tumor growth, metastasis, osteoporosis, restenosis, inflammation, macular degeneration, diabetic retinopathy, and rheumatoid arthritis |
| 02/05/2002 | US6344464 Use of tetrahydropyridine derivatives to prepare medicines for treating diseases causing demyelination |
| 01/31/2002 | WO2002008396A2 Human proteases |
| 01/31/2002 | WO2002008285A2 Il-17 molecules and uses thereof |
| 01/31/2002 | WO2002008272A2 High affinity soluble interleukin-18 receptor |
| 01/31/2002 | WO2002008271A1 Novel fibroblast growth factor (fgf23) and methods for use |
| 01/31/2002 | WO2002008268A2 Leucine-based motif and clostridial neurotoxins |
| 01/31/2002 | WO2002008255A2 Cell cycle proteins and mitosis-associated molecules |
| 01/31/2002 | WO2002008217A2 COUMARIN DERIVATIVES USEFUL AS TNFα INHIBITORS |
| 01/31/2002 | WO2002008216A1 Novel compounds and their use as glycine transport inhibitors |
| 01/31/2002 | WO2002008210A1 Cyanomethyl substituted thiazoliums and imidazoliums and treatments of disorders associated with protein aging |
| 01/31/2002 | WO2002007743A2 Piper methysticum plant extract |
| 01/31/2002 | WO2002007725A1 Method for treating fibrotic diseases or other indications ic |
| 01/31/2002 | WO2002007678A2 Mu-conopeptides |
| 01/31/2002 | WO2001038503A3 Novel human protein kinases and protein kinase-like enzymes |
| 01/31/2002 | WO2001008634A3 Polynucleotide encoding a human serine protease |
| 01/31/2002 | WO2000059941A9 Purposeful movement of human migratory cells away from an agent source |
| 01/31/2002 | US20020013374 Administering compound effective to inhibit binding of an amyloid beta peptide with alpha-7 nicotinic acetylcholine receptors |
| 01/31/2002 | US20020013357 Valdecoxib compositions |
| 01/31/2002 | US20020013349 Administering drug which opens potassium channel for reducing pain |
| 01/31/2002 | US20020013347 Tri-aryl-substituted-ethane PDE4 inhibitors |
| 01/31/2002 | US20020013341 For therapy of acute infection, acute phase response, age related macular degeneration, alcoholism, anorexia, asthma, autoimmune disease, autoimmune hepatitis, Bechet's disease, cachexia, calcium pyrophosphate dihydrtate deposition |
| 01/31/2002 | US20020013339 Nutritional and therapeutic uses of 3-hydroxyalkanoate oligomers |
| 01/31/2002 | US20020013332 Use of nicergoline for treating spasticity |
| 01/31/2002 | US20020013304 As needed rather than involving chronic pharmacotherapy; formulations and kits |
| 01/31/2002 | US20020013278 Using an interleukin-1 beta converting enzyme inhibitor pro-drug to treat apoptosis-, interferon-gamma inducing factor or interferon-gamma inducing diseases; antiinflammatory and -proliferative agents; autoimmune/degenerative disesesdiseases |
| 01/31/2002 | US20020012906 Method for kidney disease treatment by drug intervention |
| 01/31/2002 | US20020012695 Increased skin permeation of drug, and allows improved drug stability within the adhesive layer |
| 01/31/2002 | CA2418215A1 Novel fibroblast growth factor (fgf23) and methods for use |
| 01/31/2002 | CA2416988A1 Leucine-based motif and clostridial neurotoxins |
| 01/31/2002 | CA2416691A1 Proteases |
| 01/31/2002 | CA2416544A1 Mu-conopeptides |
| 01/31/2002 | CA2416447A1 Novel compounds and their use as glycine transport inhibitors |